Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD
55.80
-0.98 (-1.72%)
Aug 6, 2025, 10:43 AM EDT
-1.72%
Market Cap24.40B
Revenue (ttm)10.38B
Net Income (ttm)n/a
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PE16.87
Dividend0.57 (1.00%)
Ex-Dividend DateApr 22, 2025
Volume658
Average Volume20,964
Open56.18
Previous Close56.78
Day's Range55.80 - 56.22
52-Week Range35.61 - 60.69
Betan/a
RSI51.53
Earnings DateAug 7, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,049
Stock Exchange OTCMKTS
Ticker Symbol SDZNY
Full Company Profile

Financial Performance

Financial Statements

News

Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports

Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard ...

1 day ago - Reuters

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...

7 days ago - Accesswire

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...

7 days ago - Accesswire

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...

7 days ago - GlobeNewsWire

U.S. and European Union trade deal could cost the pharma industry up to $19 billion

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

8 days ago - Fast Company

EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

8 days ago - Reuters

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.

7 weeks ago - Fortune

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor

Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...

7 weeks ago - Benzinga

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...

2 months ago - GlobeNewsWire

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence ...

2 months ago - GlobeNewsWire

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million  up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...

3 months ago - GlobeNewsWire

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...

3 months ago - GlobeNewsWire

Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...

3 months ago - Reuters

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...

4 months ago - GlobeNewsWire

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...

4 months ago - Benzinga

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated

4 months ago - GlobeNewsWire

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News

4 months ago - GuruFocus

Switzerland's Sandoz files antitrust lawsuit against Amgen in US

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...

4 months ago - Reuters

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...

4 months ago - GlobeNewsWire

Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions

La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...

4 months ago - elEconomista.es

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...

4 months ago - GlobeNewsWire